CN112501265A - Reagent, detection method and kit for detecting CYP2D6 gene - Google Patents

Reagent, detection method and kit for detecting CYP2D6 gene Download PDF

Info

Publication number
CN112501265A
CN112501265A CN202011020314.XA CN202011020314A CN112501265A CN 112501265 A CN112501265 A CN 112501265A CN 202011020314 A CN202011020314 A CN 202011020314A CN 112501265 A CN112501265 A CN 112501265A
Authority
CN
China
Prior art keywords
cyp2d6
probe
alb
primer
detecting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011020314.XA
Other languages
Chinese (zh)
Inventor
刘汉仁
丁佳女
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Kbm Life Sciences Co ltd
Original Assignee
Hangzhou Kbm Life Sciences Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Kbm Life Sciences Co ltd filed Critical Hangzhou Kbm Life Sciences Co ltd
Priority to CN202011020314.XA priority Critical patent/CN112501265A/en
Publication of CN112501265A publication Critical patent/CN112501265A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a CYP2D6 genotyping detection kit, which comprises a detection primer and a probe of CYP2D6 x 10, and a detection primer and a probe of an internal reference gene ALB. The invention can distinguish CYP2D6 x 10 and CYP2D6 x 5 by amplifying CYP2D6 and internal reference (ALB) genes. Provides a new way for simple judgment for clinical medication guidance.

Description

Reagent, detection method and kit for detecting CYP2D6 gene
Technical Field
The invention relates to the fields of molecular biology and medicine, in particular to a polymorphism detection reagent, a kit and a detection method for drug metabolism related genes CYP2D 6.
Background
According to the publication of the World Health Organization (WHO), the proportion of the patients WHO are hospitalized in all countries of the world to suffer from the adverse drug reactions is 10% -20%, wherein 5% of the patients die of the serious adverse drug reactions. Therefore, pharmacogenomics research has become a global focus, and personalized medicine and personalized treatment are the key points of discussion of international academic conference of various medical biology.
Cytochrome (CYP)2D6 is one of important members of CYP450 family, although the total amount only accounts for 2% -9% of liver enzymes, the Cytochrome (CYP)2D6 participates in 20% -30% of clinical drug metabolism, and comprises more than 80 drugs such as antihypertensive drugs, antidepressant drugs, antiarrhythmic drugs, antipsychotic drugs, antitumor drugs and the like.
There are many polymorphisms in the CYP2D6 gene, and more than 100 mutation sites have been found so far. Among them, the normal allele CYP2D6 x 1, the intermediate metabolic allele CYP2D6 x 10 and the slow metabolic allele CYP2D6 x 5 are the most common. CYP2D6 × 10 is 188C mutation on the 1 st exon of CYP2D6 is T, the allele frequency is 51.6%, CYP2D6 × 5 is deletion of the whole CYP2D6 gene, and the occurrence frequency is 3% -7%.
The Taqman probe fluorescence PCR method is a common SNP typing method, the method is mature in technology and can be developed into a commercialized kit. However, if the common Taqman probe method is used to type CYP2D6, there is a first problem that only CYP2D6 × 10 can be typed, and CYP2D6 × 5 cannot be typed.
The interpretation of the results of the polymorphism detection of the gene CYP2D6 is troubled by the CYP2D6 x 10 typing, which considers only the 188C mutation T on the 1 st exon of CYP2D6, and the CYP2D6 x 5 typing, which does not consider the deletion of the entire CYP2D6 gene. Since human beings have deletion mutations of CYP2D6 x 5 type, when the Taqman probe method is used to classify CYP2D6 x 10, there is no fluorescence signal when the deletion mutation of CYP2D6 x 5 type is encountered. In this case, the operator cannot judge whether the absence of the fluorescence signal is caused by various incidental factors such as too low a DNA concentration or degradation of the sample, an erroneous sample due to an operation error, and an unstable PCR system, or whether the sample itself is a deletion mutation of CYP2D6 × 5 type. Therefore, it is urgently needed to develop a new detection reagent and a new detection method which can simultaneously judge whether the gene CYP2D6 in a sample is wild-type CYP2D6 x 1, mutant CYP2D6 x 10 or deletion CYP2D6 x 5.
Disclosure of Invention
The invention provides a detection kit for judging mutant type and deletion type of CYP2D6 gene aiming at the defect of the existing Taqman probe fluorescence PCR method for detecting CYP2D6, and the detection kit comprises a primer and a probe for detecting CYP2D6 x 10, and a primer and a probe for detecting internal reference gene ALB.
The sequences of the primer and the probe for detecting CYP2D6 × 10 are respectively as follows:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3'
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3'
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNBNFQ
The sequences of primers and probes for detecting the internal reference gene ALB are respectively as follows:
ALB upstream primer: 5'-TTGTGGGCTGTAATCATCGTCTA-3'
ALB downstream primer: 5'-GTTCTCTTTCACTGACATCTGCAAA-3'
ALB probe: CY5-CCCACACAAATCTCTCCCTGGCATTG-BHQ 3.
The invention also provides application of the primer and the probe in a drug-directed analysis kit.
The invention also provides a method for detecting the polymorphism of the CYP2D6 gene. The method comprises the following steps:
(1) extracting genomic DNA in a sample;
(2) and (3) performing fluorescent quantitative PCR on the DNA obtained in the step (1), wherein PCR reaction reagents comprise primers and probes for detecting CYP2D6 x 10 and primers and probes for detecting an internal reference gene ALB.
(3) And (5) judging the result. If CY5 and FAM have signals, the signal is CYP2D6 x 1 wild type; if CY5 and VIC have signals, the mutant is CYP2D6 x 10 homozygous mutant; if CY5, FAM and VIC have signals, the mutant is CYP2D6 x 1/x 10 hybrid mutant; if only CY5 has a signal, it is CYP2D6 × 5 type.
In the present invention, CYP2D6 × 1 indicates that the first exon of the gene CYP2D6 is wild type; CYP2D6 × 10 indicates a mutant form of 188C mutation to T on exon 1 of the gene CYP2D 6; CYP2D6 x 1/' 10 represents a hybrid mutant; CYP2D6 × 5 indicates a deletion type in which the entire CYP2D6 gene was deleted.
Compared with the prior art, the method can accurately detect the CYP2D6 x 10(188C > T) gene polymorphism in human peripheral blood samples, and the detectable polymorphism types comprise CYP2D6 x 1 wild type (C/C), CYP2D6 x 1/x 10 heterozygous mutant type (C/T), CYP2D6 x 10 homozygous mutant type (T/T) and CYP2D6 x 5 gene deletion type. The specific analysis is as follows:
1. the CYP2D6 x 1 homozygous wild type, CYP2D6 x 1/10 heterozygous mutant and CYP2D6 x 10 homozygous mutant can be distinguished in one reaction by specifically designing the CYP2D6 x 1 wild type probe and the CYP2D6 x 10 mutant probe.
2. The first function of the internal reference gene ALB in the invention is to judge whether the fluorescent quantitative PCR reaction is normal or not, and the second function is to judge whether a gene deletion type exists or not. The CYP2D6 x 5 gene deletion type is judged by a method of adding internal reference gene detection, and when the wild type and the mutant type of CYP2D6 x 10 have no signals, and the internal reference has signals, the gene deletion can be judged.
3. By using the optimized reaction system, the amplification of CYP2D6 and the internal reference gene ALB are simultaneously carried out in one PCR reaction hole, so that the cost is saved, the error between the holes can be completely avoided, and the reliability of the result is ensured.
4. The reaction system used in the invention has strong anti-inhibitor capability, and can amplify DNA samples and also directly amplify blood or blood pretreatment substances.
5. The whole method only needs one fluorescence PCR reaction, and the manual operation time, so that the whole detection only needs less than 2 hours, and the method has the advantages of time saving and labor saving.
Drawings
Fig. 1 amplification curve of CYP2D6 x 1 wild type (C/C).
FIG. 2 amplification curves for CYP2D6 x 10 homozygous mutant (T/T).
FIG. 3 amplification curves for CYP2D6 x 1/' 10 hybrid mutant (C/T).
Figure 4 amplification curve of CYP2D6 x 5 type deletion.
FIG. 5 amplification curves for the blank control.
Figure 6CYP2D6 × 10 wild type (C/C) generation sequencing map.
Figure 7CYP2D6 × 10 mutant (T/T) generation sequencing map.
FIG. 8CYP2D6 x 10 hybrid (C/T) generation sequencing profile.
FIG. 9 electrophoretogram of example 3.
Detailed Description
The invention provides a kit and a method capable of simultaneously typing CYP2D6 x 10 and CYP2D6 x 5. The specific fluorescent probe is combined with the real-time fluorescent PCR technology to detect the gene polymorphism of human CYP2D6 x 10(188C > T). According to the site sequence of human CYP2D6 x 10(188C > T) gene, a wild type probe and a mutant type probe with high specificity and an ALB reference gene probe are designed respectively and are marked by different fluorescent signal groups respectively. When the specific probe is completely complementary and matched with the corresponding allele type template, after the probe is combined with the template, the probe is hydrolyzed to generate a fluorescent signal and generate a corresponding Ct value. Human CYP2D6 (188C > T) genotype or CYP2D6 x 5 was judged on a fluorescence quantitative PCR instrument from information of fluorescence signals (Ct values) forming an amplification curve.
Example 1 detection kit Using fluorescent quantitative PCR detection System
The detection kit comprises an amplification primer, a probe and other matched reagents for carrying out fluorescent quantitative PCR detection. Amplification primers and probes were designed against both CYP2D6 gene CYP2D6 x 10 and CYP2D6 x 5 types.
First, design and synthesis of amplification primer
CYP2D6 × 10 was based on the 188C → T mutation on the 1 st exon of CYP2D6, and the primers and probes for detecting CYP2D6 × 10 were:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3'
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3'
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNBNFQ
CYP2D6 × 5 is the deletion of the whole CYP2D6 gene, and the primers and probes for detecting CYP2D6 × 5 comprise the primers and probes for CYP2D6 × 10 and an internal reference gene ALB, which are respectively as follows:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3' (SEQ 1)
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3' (SEQ 2)
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ (SEQ 3)
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNFQ (SEQ 4)
ALB upstream primer: 5'-TTGTGGGCTGTAATCATCGTCTA-3' (SEQ 5)
ALB downstream primer: 5'-GTTCTCTTTCACTGACATCTGCAAA-3' (SEQ 6)
ALB probe: CY5-CCCACACAAATCTCTCCCTGGCATTG-BHQ3(SEQ 7)
The fluorescent signal group marked on the probe in this embodiment is only a specific embodiment, and one skilled in the art can also select different fluorescent signal groups to mark according to needs.
The composition of the kit is shown in table 1.
TABLE 1
Figure BDA0002700431130000051
Example 2 fluorescent quantitative PCR detection method
A method of simultaneously typing CYP2D6 x 10 and CYP2D6 x 5, comprising the steps of:
(1) blood pretreatment: the blood pretreatment reagent includes TE Buffer. The blood pretreatment method comprises taking 80 μ L of whole blood sample, placing in a 1.5mL centrifuge tube, adding 1mL purified water, mixing by inversion, and centrifuging at 12000 × g for 1 min. Discard the supernatant, add 50. mu.L of 1 XTE Buffer, vortex and mix well, resuspend the pellet to obtain the blood pretreatment.
(2) Fluorescent PCR system
Reaction components Test sample Positive control Negative control
CYP2D6 × 10PCR reaction solution 17.6μL 17.6μL 17.6μL
Reaction enzyme 0.4μL 0.4μL 0.4μL
Blood pretreatment 2μL / /
CYP2D6 x 10 positive control / 2μL /
CYP2D6 x 10 negative control / / 2μL
(3) Fluorescent PCR procedure
Figure BDA0002700431130000052
Figure BDA0002700431130000061
"+" indicates fluorescence signal collection site
(4) Interpretation of results
Ct value interpretation method:
Figure BDA0002700431130000062
if the Ct value of the internal reference signal CY5 is greater than 30, the sample is abnormal, and the sample needs to be reprocessed or collected again. The amplification curve interpretation method is shown in FIGS. 1 to 5.
The optimized PCR reaction solution adopted by the invention has strong anti-inhibitor capability, can amplify blood pretreatment substances, is not limited to the blood pretreatment substances, and can amplify extracted DNA samples or directly amplify blood as a template.
Example 3 analysis of clinical samples Using fluorescent quantitative PCR
32 clinical specimens were collected, genomic DNA was extracted using a commercial column extraction kit, and clinical specimens for CYP2D6 gene polymorphism were developed in examples 1 and 2. Meanwhile, the first-generation sequencing method is used for carrying out genotyping detection on the extracted DNA, and the genotyping result of the method is compared with the genotyping result of the first-generation sequencing. The results are shown in Table 2, with 100% accuracy. The sequencing results for the three genotypes C/C, C/T and T/T are shown in FIGS. 6 to 8.
Table 2:
Figure BDA0002700431130000063
sequencing validation method for CYP2D6 × 5 type:
this method is derived from the literature: hersberger M, Marti-Jaun J, Rentsch K, et al Rapid detection of the CYP2D6 x 3, CYP2D6 x 4, and CYP2D6 x 6 alloys by four primer PCR and of the CYP2D6 x 5 alloys by multiplex Long PCR [ J ]. Clinical Chemistry,2000, 46(8I): 1072-. The specific method comprises the following steps:
an amplification primer:
Figure BDA0002700431130000071
PCR reaction system
Figure BDA0002700431130000072
The template is 1 sample of C/C, C/T and T/T type, 2 samples of CYP2D6 x 5 deletion type.
PCR procedure:
Figure BDA0002700431130000073
Figure BDA0002700431130000081
sequencing analysis: the amplification product is sent to sequencing. The result shows that the typing result of the fluorescence PCR is consistent with the genotype of the sequencing result. The 5.1kb (CYP2D6 non-deleted) sequence is shown in SEQ 8, and the 3.5kb (CYP2D6 deleted) sequence is shown in SEQ 9.
5.1kb (CYP2D6 non-deleted) sequence (SEQ 8), wherein Y represents C or T. The wild type sequence Y is C, and the mutant type sequence Y is T.
GTTATCCCAGAAGGCTTTGCAGGCTTCAGGAGCTTGGAGTGGGGAGAGGGGGTGACT TCTCCGACCAGGCCCCTCCACCGGCCTACCCTGGGTAAGGGCCTGGAGCAGGAAGCA GGGGCAAGAACCTCTGGAGCAGCCCATACCCGCCCTGGCCTGACTCTGCCACTGGCA GCACAGTCAACACAGCAGGTTCACTCACAGCAGAGGGCAAAGGCCATCATCAGCTCC CTTTATAAGGGAAGGGTCACGCGCTCGGTGTGCTGAGAGTGTCCTGCCTGGTCCTCTG TGCCTGGTGGGGTGGGGGTGCCAGGTGTGTCCAGAGGAGCCCATTTGGTAGTGAGGC AGGTATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCC TGGTGGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACY(C>T)
CACCAGGCCCCCTGCCACTGCCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAA CACACCATACTGCTTCGACCAGGTGAGGGAGGAGGTCCTGGAGGGCGGCAGAGGTGC TGAGGCTCCCCTACCAGAAGCAAACATGGATGGTGGGTGAAACCACAGGCTGGACCA GAAGCCAGGCTGAGAAGGGGAAGCAGGTTTGGGGGACKTCCTGGAGAAGGGCATTTA TACATGGCATGAAGGACTGGATTTTCCAAAGGCCAAGGAAGAGTAGGGCAAGGGCCT GGAGGTGGAGCTGGACTTGGCAGTGGGCATGCAAGCCCATTGGGCAACATATGTTATG GAGTACAAAGTCCCTTCTGCTGACACCAGAAGGAAAGGCCTTGGGAATGGAAGATGA GTTAGTCCTGAGTGCCGTTTAAATCACGAAATCGAGGATGAAGGGGGTGCAGTGACCC GGTTCAAACCTTTTGCACTGTGGGTCCTCGGGCCTCACTGCTCACCGGCATGGACCAT CATCTGGGAATGGGATGCTAACTGGGGCCTCTCGGCAATTTTGGTGACTCTTGCAAGGT CATACCTGGGTGACGCATCCAAACTGAGTTCCTCCATCACAGAAGGTGTGACCCCCAC CCCCGCCCCACGATCAGGAGGCTGGGTCTCCTCCTTCCACCTGCTCACTCCTGGTAGC CCCGGGGGTCGTCCAAGGTTCAAATAGGACTAGGACCTGTAGTCTGGGGDGATCCTGG CTTGACAAGAGGCCCTGACCCTCCCTCTGCAGTTGCGGCGCCGCTTCGGGGACGTGTT CAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTGCTCAATGGGCTGGCGGCCGTGCG CGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGACCGCCCGCCTGTGCCCATCAC CCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGCAAGCAGCGGTGGGGACAGAGACA GATTTCCGTGGGACCCGGGTGGGTGATGACCGTAGTCCGAGCTGGGCAGAGAGGGCG CGGGGTCGTGGACATGAAACAGGCCAGCGAGTGGGGACAGCGGGCCAAGAAACCAC CTGCACTAGGGAGGTGTGAGCATGGGGACGAGGGCGGGGCTTGTGACGAGTGGGCGG GGCCACTGCCGAGACCTGGCAGGAGCCCAATGGGTGAGGCTGGCGCATTTCCCAGCT GGAATCCGGTGTCGAAGTGGGGGGCGGGGACCGCACCTGTGCTGTAAGCTCAGTGTG GGTGGCGCGGGGCCCGCGGGGTCTTCCCTGAGTGCAAAGGCGGTCAGGGTGGGCAGA GACGAGGTGGGGCAAAGCCCTGCCCCAGCCAAGGGAGCAAGGTGGATGCACAAAGA GTGGGCCCTGTGACCAGCTGGACAGAGCCAGGGACTGCGGGAGACCAGGGGGAGCAT AGGGTTGGAGTGGGTGGTGGATGGTGGGGCTAATGCCTTCATGGCCACGCGCACGTGC CCGTCCCACCCCCAGGGGTGTTCCTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGA GGCGCTTCTCCGTGTCCACCTTGCGCAACTTGGGCCTGGGCAAGAAGTCGCTGGAGC AGTGGGTGACCGAGGAGGCCGCCTGCCTTTGTGCCGCCTTCGCCAACCACTCCGGTG GGTGATGGGCAGAAGGGCACAAAGCGGGAACTGGGAAGGCGGGGGACGGGGAAGG CGACCCCTTACCCGCATCTCCCACCCCCAGGACGCCCCTTTCGCCCCAACGGTCTCTTG GACAAAGCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACG ACGACCCTCGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGT CGGGCTTTCTGCGCGAGGTGCGGAGCGAGAGACCGAGGAGTCTCTGCAGGGCGAGCT CCCGAGAGGTGCCGGGGCTGGACTGGGGCCTCGGAAGAGCAGGATTTGCATAGATGG GTTTGGGAAAGGACATTCCAGGAGACCCCACTGTAAGAAGGGCCTGGAGGAGGAGGG GACATCTCAGACATGGTCGTGGGAGAGGTGTGCCCGGGTCAGGGGGCACCAGGAGAG GCCAAGGACTCTGTACCTCCTATCCACGTCAGAGATTTCGATTTTAGGTTTCTCCTCTG GGCAAGGAGAGAGGGTGGAGGCTGGCACTTGGGGAGGGACTTGGTGAGGTCAGTGG TAAGGACAGGCAGGCCCTGGGTCTACCTGGAGATGGCTGGGGCCTGAGACTTGTCCA GGTGAACGCAGAGCACAGGAGGGATTGAGACCCCGTTCTGTCTGGTGTAGGTGCTGA ATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTCCTACGCTTCCAA AAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATGACCTGGGACC CAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAGAAGGTGA GAGTGGCTGCCACGGTGGGGGGCAAGGGTGGTGGGTTGAGCGTCCCAGGAGGAATG AGGGGAGGCTGGGCAAAAGGTTGGACCAGTGCATCACCCGGCGAGCCGCATCTGGGC TGACAGGTGCAGAATTGGAGGTCATTTGGGGGCTACCCCGTTCTGTCCCGAGTATGCT CTCGGCCCTGCTCAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTG CGCATAGTGGTGGCTGACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGG CCTGGGGCCTCCTGCTCATGATCCTACATCCGGATGTGCAGCGTGAGCCCATCTGGGAA ACAGTGCAGGGGCCGAGGGAGGAAGGGTACAGGCGGGGGCCCATGAACTTTGCTGG GACACCCGGGGCTCCAAGCACAGGCTTGACCAGGATCCTGTAAGCCTGACCTCCTCCA ACATAGGAGGCAAGAAGGAGTGTCAGGGCCGGACCCCCTGGGTGCTGACCCATTGTG GGGACGCATGTCTGTCCAGGCCGTGTCCAACAGGAGATCGACGACGTGATAGGGCAG GTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATTC ATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGTAGGCCTGGCGCCCTCCTCACCCC AGCTCAGCACCAGCACCTGGTGATAGCCCCAGCATGGCTACTGCCAGGTGGGCCCACT CTAGGAACCCTGGCCACCTAGTCCTCAATGCCACCACACTGACTGTCCCCACTTGGGT GGGGGGTCCAGAGTATAGGCAGGGCTGGCCTGTCCATCCAGAGCCCCCGTCTAGTGGG GAGACAAACCAGGACCTGCCAGAATGTTGGAGGACCCAACGCCTGCAGGGAGAGGG GGCAGTGTGGGTGCCTCTGAGAGGTGTGACTGCGCCCTGCTGTGGGGTCGGAGAGGG TACTGTGGAGCTTCTCGGGCGCAGGACTAGTTGACAGAGTCCAGCTGTGTGCCAGGCA GTGTGTGTCCCCCGTGTGTTTGGTGGCAGGGGTCCCAGCATCCTAGAGTCCAGTCCCC ACTCTCACCCTGCATCTCCTGCCCAGGGAACGACACTCATCACCAACCTGTCATCGGT GCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTCCTG GATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGTGCCT GTGGGGAGCCCGGCTCCCTGTCCCCTTCCGTGGAGTCTTGCAGGGGTATCACCCAGGA GCCAGGCTCACTGACGCCCCTCCCCTCCCCACAGGCCGCCGTGCATGCCTCGGGGAGC CCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTGCTGCAGCACTTCAGCTTC TCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTCTTTGCTTTCCTGGTGA GCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAGAATGGGGTACCTAGTCCCCAG CCTGCTCCCTAGCCAGAGGCTCTAATGTACAATAAAGCAATGTGGTAGTTCCAACTCGG GTCCCCTGCTCACGCCCTCGTTGGGATCATCCTCCTCAGGGCAACCCCACCCCTGCCTC ATTCCTGCTTACCCCACCGCCTGGCCGCATTTGAGACAGGGGTACGTTGAGGCTGAGC AGATGTCAGTTACCCTTGCCCATAATCCCATGTCCCCCACTGACCCAACTCTGACTGCC CAGATTGGTGACAAGGACTACATTGTCCTGGCATGTGGGGAAGGGGCCAGAATGGGCT GACTAGAGGTGTCAGTCAGCCCTGGATGTGGTGGAGAGGGCAGGACTCAGCCTGGAG GCCCATATTTCAGGCCTAACTCAGCCCACCCCACATCAGGGACAGCAGTCCTGCCAGC ACCATCACAACAGTCACCTCCCTTCATATATGACACCCCAAAACGGAAGACAAATCAT GGCGTCAGGGAGCTATATGCCAGGGCTACCTACCTCCCAGGGCTCAGTCGGC
3.5kb (CYP2D6 deleted) sequence (SEQ 9):
CACACCGGGCACCTGTACTCCTCAGCCCTTGGGCAGTGGACGGGACCAGG TGCCGTGGAGCAGTGGGAGGCACCCATCCGGGAGGCTCGGGCCTCGCAGG GAGCCCACCGTAGGGAGGCTTGGGCATGGCAGGCTGCAAGTCCTGAGCCC TGCCCCGCGGGGAGGTGACTGAGGCCTGGCGACAATTCAAGTGTGGTGAG CGCCGGCAGGCCAGCAGTACTGGGGGACCCGGTGCCCCCTCTGCAGCTGC TGGCCCAGGTGCTAAGCCCCTCACTGCCTGGGGCCAGAGGCACCAGCCGG CCGCTCCGAGTGCAGGGCCCGCTGAGCCCCTGCCCACCCAGAACTGGTGC TGGCCCGCGAGCAACCCAGGTTCCCGCACACGCCTCTCCCTCCATACCTCC CCGCAAGCAGACGGAGCCGGCTCCAGCCTCCACCAGTCCAGAGAGGGGC TCCCACAGTGCAGCGCTGGGCTGAAGGGCTCCTCAAGTGTGGTCAGAGCA GAAGCTGAGGCCGAGGAGGCGCTGAGAGCGAGCGAGGACCACCAGCACG TTGACACCTCTCAACCTCACCACAGGACTGGCCACCTCTCTGGGCCCTCAG GGATGCTGCTGTCTGGACCCCTGACCAGTGACGAGTTCGCACTCAGGGCC AGGCTGGCGCTGGAGGAGGACACTTGTTTGGCTCCAACCCTAGGTACCATC CTCCCAGTAGGGATCAGGCAGGGCCCACAGGCCTGCCCTAGGGACAGGAG TCAACCTTGGACCCATAAGGCACTGGGGCGGGCAGAGAAGGAGGAGGTG GCATGGGCAGCTGAGAGCCAGAGACCCTGACCCTAGTCCTTGCTCTGCCAT TACCCCGTGTGACCCCGGGCCCACCCTTCCCCACCCTTCCCCACCCTTCCC CACCCCGGGCTTCTGTTTCCCTTCTGCCAACGAGAAGGCTGCTTCACCTGC CCCGAGTCCTGTCTTCCTGCTCTGCCTTCTGGGGCTGTGGCCCTTGCTGGC CTGGAGCCCCAACCAAGGGCAGGGACTGCTGTCCTCCACGTCTGTCCTCA CCGACATAATGGGCTGGGCTGGGCACACAGGCAGTGCCCAAGAGTTTCTA ATGAGCATATGATTACCTGAGTCCTGGGCAGACCTTCTTAGGGAACAGCCT GGGACAGAGAACCACAGACACTCTGAGGAGCCACCTGAGGCCTCTTTTGC CAGAGGACCCTACAGCCTCCCTGGCAGCAGTTCCGCCAGCATTTCTGTAAA TGCCCTCATGCCAGGGTGCGGCCCGGCTGTCAGCACGAGAGGGACGTTGG TCTGTCCCCTGGCACCGAGTCAGTCAGAAGGGTGGCCAGGGCCCCCTTGG GCCCCTCCAGAGACAATCCACTGTGGTCACACGGCTCGGTGGCAGGAAGT GCTGTTCCTGCAGCTGTGGGGACAGGGAGTGTGGATGAAGCCAGGCTGGG TTTGTCTGAAGACGGAGGCCCCGAAAGGTGGCAGCCTGGCCTATAGCAGC AGCAACTCTTGGATTTATTGGAAAGATTTTCTTCACGGTTCTGAGTCTTGGG GGTGTTAGAGGCTCAGAACCAGTCCAGCCAGAGCTCTGTCATGGGCACGT AGACCCGGTCCCAGGGCCTTTGCTCTTTGCTGTCCTCAGAGGCCTCTGCAA AGTAGAAACAGGCAGCCTTGTGAGTCCCCTCCTGGGAGCAACCAACCCTC CCTCTGAGATGCCCCGGGGCCAGGTCAGCTGTGGTGAAAGGTAGGGATGC AGCCAGCTCAGGGGAGTGGCCCAGAGTTCCTGCCCACCCAAGGAGGCTCC CAGGAAGGTCAAGGCACCTGACTCCTGGGCTGCTTCCCTCCCCTCCCCTCC CCAGGTCAGGAAGGTGGGAAAGGGCTGGGGTGTCTGTGACCCTGGCAGTC ACTGAGAAGCAGGGTGGAAGCAGCCCCCTGCAGCACGCTGGGTCAGTGG TCTTACCAGATGGATACGCAGCAACTTCCTTTTGAACCTTTTTATTTTCCTG GCAGGAAGAAGAGGGATCCAGCAGTGAGATCAGGCAGGTTCTGTGTTGCA CAGACAGGGAAACAGGCTCTGTCCACACAAAGTCGGTGGGGCCAGGATG AGGCCCAGTCTGTTCACACATGGCTGCTGCCTCTCAGCTCTGCACAGACGT CCTCGCTCCCCTGGGATGGCAGCTTGGCCTGCTGGTCTTGGGGTTGAGCCA GCCTCCAGCACTGCCTCCCTGCCCTGCTGCCTCCCACTCTGCAGTGCTCCA TGGCTGCTCAGTTGGACCCACGCTGGAGACGTTCAGTCGAAGCCCCGGGC TGTCCTTACCTCCCAGTCTGGGGTACCTGCCACCTCCTGCTCAGCAGGAAT GGGGCTAGGTGCTTCCTCCCCTGGGGACTTCACCTGCTCTCCCTCCTGGGA TAAGACGGCAGCCTCCTCCTTGGGGGCAGCAGCATTCAGTCCTCCAGGTCT CCTGGGGGTCGTGACCTGCAGGAGGAATAAGAGGGCAGACTGGGCAGAA AGGCCTTCAGAGCACCTCATCCTCCTGTTCTCACACTGGGGTGTCACAGTC CTGGGAAGTTCTTCCTTTTCAGTTGAGCTGTGGTAACCTTGTGAGTTTCCTG GAGGGGGCCTGCCACTACCCTTGGGACTCCCTGCCGTGTGTCTGGGTCTAA CTGAGCTCTGAAAGGAGAGAGCCCCAGCCCTGGGCCTTCCAGGGGAAGCC TTACCTCAGAGGTTGGCTTCTTCCTACTCTTGACTTTGCGTCTCTGCAGAGG GAGGTGGGAGGGGTGACACAACCCTGACACCCACACTATGAGTGATGAGT AGTCCTGCCCCGACTGGCCCATCCTTTCCAGGTGCAGTCCCCCTTACTGTG TCTGCCAAGGGTGCCAGCACAGCCGCCCCACTCCAGGGGAAGAGGAGTG CCAGCCCTTACCCACCTGAGTGGGCACAGTGTAGCATTTATTCATTAGCCCC CACACTGGCCTGACCATCTCCCCTGTGGGCTGCATGACAAGGAGAGAGAA CAGGCTGAGGTGAGAGCTACTGTCAACACCTAAACCTAAAAAATCTATAAT TGGGCTGGGCAGGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCC GAGATGGGTGGATCACCTGAGGTCAGATGTTCGAGACCAGCCTGGCCAAC ATGGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCTGGGCGTGGT GGTGGGTGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATTG CTTGAACCTGGGAGGCAGAGGCTGCAGTGAGCCGAGATCGCATCATTGCA CTCCAGCCTGGTCAACAAGAGTGAAACTGTCTTAAAAAAAAAATCTATAAT TGATATCTTTAGAAAGATAAAACTTTGCATTCATGAAATAAGAATAGGAGGG TCTAAAATAAAAATGTTCAAACACCCACCACCACTAATTCTTGACAAAAAT ATAGTCTGGGTGCCTTAGCTCATGCCTG
electrophoresis: and carrying out electrophoretic analysis on the amplification product. The results of the analysis are shown in FIG. 9.
Sequence listing
<110> Hangzhou Baimai biological shares Ltd
<120> reagent, detection method and kit for detecting CYP2D6 gene
<130> 202002
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
ccatttggta gtgaggcagg t 21
<210> 2
<211> 17
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
atgcagcagg ttgccca 17
<210> 3
<211> 16
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
cacgctaccc accagg 16
<210> 4
<211> 15
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
acgctactca ccagg 15
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ttgtgggctg taatcatcgt cta 23
<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
gttctctttc actgacatct gcaaa 25
<210> 7
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
cccacacaaa tctctccctg gcattg 26
<210> 8
<211> 5104
<212> DNA
<213> Human Gene Sequence (Human Gene Sequence)
<400> 8
gttatcccag aaggctttgc aggcttcagg agcttggagt ggggagaggg ggtgacttct 60
ccgaccaggc ccctccaccg gcctaccctg ggtaagggcc tggagcagga agcaggggca 120
agaacctctg gagcagccca tacccgccct ggcctgactc tgccactggc agcacagtca 180
acacagcagg ttcactcaca gcagagggca aaggccatca tcagctccct ttataaggga 240
agggtcacgc gctcggtgtg ctgagagtgt cctgcctggt cctctgtgcc tggtggggtg 300
ggggtgccag gtgtgtccag aggagcccat ttggtagtga ggcaggtatg gggctagaag 360
cactggtgcc cctggccgtg atagtggcca tcttcctgct cctggtggac ctgatgcacc 420
ggcgccaacg ctgggctgca cgctacycac caggccccct gccactgccc gggctgggca 480
acctgctgca tgtggacttc cagaacacac catactgctt cgaccaggtg agggaggagg 540
tcctggaggg cggcagaggt gctgaggctc ccctaccaga agcaaacatg gatggtgggt 600
gaaaccacag gctggaccag aagccaggct gagaagggga agcaggtttg ggggacktcc 660
tggagaaggg catttataca tggcatgaag gactggattt tccaaaggcc aaggaagagt 720
agggcaaggg cctggaggtg gagctggact tggcagtggg catgcaagcc cattgggcaa 780
catatgttat ggagtacaaa gtcccttctg ctgacaccag aaggaaaggc cttgggaatg 840
gaagatgagt tagtcctgag tgccgtttaa atcacgaaat cgaggatgaa gggggtgcag 900
tgacccggtt caaacctttt gcactgtggg tcctcgggcc tcactgctca ccggcatgga 960
ccatcatctg ggaatgggat gctaactggg gcctctcggc aattttggtg actcttgcaa 1020
ggtcatacct gggtgacgca tccaaactga gttcctccat cacagaaggt gtgaccccca 1080
cccccgcccc acgatcagga ggctgggtct cctccttcca cctgctcact cctggtagcc 1140
ccgggggtcg tccaaggttc aaataggact aggacctgta gtctggggdg atcctggctt 1200
gacaagaggc cctgaccctc cctctgcagt tgcggcgccg cttcggggac gtgttcagcc 1260
tgcagctggc ctggacgccg gtggtcgtgc tcaatgggct ggcggccgtg cgcgaggcgc 1320
tggtgaccca cggcgaggac accgccgacc gcccgcctgt gcccatcacc cagatcctgg 1380
gtttcgggcc gcgttcccaa ggcaagcagc ggtggggaca gagacagatt tccgtgggac 1440
ccgggtgggt gatgaccgta gtccgagctg ggcagagagg gcgcggggtc gtggacatga 1500
aacaggccag cgagtgggga cagcgggcca agaaaccacc tgcactaggg aggtgtgagc 1560
atggggacga gggcggggct tgtgacgagt gggcggggcc actgccgaga cctggcagga 1620
gcccaatggg tgaggctggc gcatttccca gctggaatcc ggtgtcgaag tggggggcgg 1680
ggaccgcacc tgtgctgtaa gctcagtgtg ggtggcgcgg ggcccgcggg gtcttccctg 1740
agtgcaaagg cggtcagggt gggcagagac gaggtggggc aaagccctgc cccagccaag 1800
ggagcaaggt ggatgcacaa agagtgggcc ctgtgaccag ctggacagag ccagggactg 1860
cgggagacca gggggagcat agggttggag tgggtggtgg atggtggggc taatgccttc 1920
atggccacgc gcacgtgccc gtcccacccc caggggtgtt cctggcgcgc tatgggcccg 1980
cgtggcgcga gcagaggcgc ttctccgtgt ccaccttgcg caacttgggc ctgggcaaga 2040
agtcgctgga gcagtgggtg accgaggagg ccgcctgcct ttgtgccgcc ttcgccaacc 2100
actccggtgg gtgatgggca gaagggcaca aagcgggaac tgggaaggcg ggggacgggg 2160
aaggcgaccc cttacccgca tctcccaccc ccaggacgcc cctttcgccc caacggtctc 2220
ttggacaaag ccgtgagcaa cgtgatcgcc tccctcacct gcgggcgccg cttcgagtac 2280
gacgaccctc gcttcctcag gctgctggac ctagctcagg agggactgaa ggaggagtcg 2340
ggctttctgc gcgaggtgcg gagcgagaga ccgaggagtc tctgcagggc gagctcccga 2400
gaggtgccgg ggctggactg gggcctcgga agagcaggat ttgcatagat gggtttggga 2460
aaggacattc caggagaccc cactgtaaga agggcctgga ggaggagggg acatctcaga 2520
catggtcgtg ggagaggtgt gcccgggtca gggggcacca ggagaggcca aggactctgt 2580
acctcctatc cacgtcagag atttcgattt taggtttctc ctctgggcaa ggagagaggg 2640
tggaggctgg cacttgggga gggacttggt gaggtcagtg gtaaggacag gcaggccctg 2700
ggtctacctg gagatggctg gggcctgaga cttgtccagg tgaacgcaga gcacaggagg 2760
gattgagacc ccgttctgtc tggtgtaggt gctgaatgct gtccccgtcc tcctgcatat 2820
cccagcgctg gctggcaagg tcctacgctt ccaaaaggct ttcctgaccc agctggatga 2880
gctgctaact gagcacagga tgacctggga cccagcccag cccccccgag acctgactga 2940
ggccttcctg gcagagatgg agaaggtgag agtggctgcc acggtggggg gcaagggtgg 3000
tgggttgagc gtcccaggag gaatgagggg aggctgggca aaaggttgga ccagtgcatc 3060
acccggcgag ccgcatctgg gctgacaggt gcagaattgg aggtcatttg ggggctaccc 3120
cgttctgtcc cgagtatgct ctcggccctg ctcaggccaa ggggaaccct gagagcagct 3180
tcaatgatga gaacctgcgc atagtggtgg ctgacctgtt ctctgccggg atggtgacca 3240
cctcgaccac gctggcctgg ggcctcctgc tcatgatcct acatccggat gtgcagcgtg 3300
agcccatctg ggaaacagtg caggggccga gggaggaagg gtacaggcgg gggcccatga 3360
actttgctgg gacacccggg gctccaagca caggcttgac caggatcctg taagcctgac 3420
ctcctccaac ataggaggca agaaggagtg tcagggccgg accccctggg tgctgaccca 3480
ttgtggggac gcatgtctgt ccaggccgtg tccaacagga gatcgacgac gtgatagggc 3540
aggtgcggcg accagagatg ggtgaccagg ctcacatgcc ctacaccact gccgtgattc 3600
atgaggtgca gcgctttggg gacatcgtcc ccctgggtgt gacccatatg acatcccgtg 3660
acatcgaagt acagggcttc cgcatcccta aggtaggcct ggcgccctcc tcaccccagc 3720
tcagcaccag cacctggtga tagccccagc atggctactg ccaggtgggc ccactctagg 3780
aaccctggcc acctagtcct caatgccacc acactgactg tccccacttg ggtggggggt 3840
ccagagtata ggcagggctg gcctgtccat ccagagcccc cgtctagtgg ggagacaaac 3900
caggacctgc cagaatgttg gaggacccaa cgcctgcagg gagagggggc agtgtgggtg 3960
cctctgagag gtgtgactgc gccctgctgt ggggtcggag agggtactgt ggagcttctc 4020
gggcgcagga ctagttgaca gagtccagct gtgtgccagg cagtgtgtgt cccccgtgtg 4080
tttggtggca ggggtcccag catcctagag tccagtcccc actctcaccc tgcatctcct 4140
gcccagggaa cgacactcat caccaacctg tcatcggtgc tgaaggatga ggccgtctgg 4200
gagaagccct tccgcttcca ccccgaacac ttcctggatg cccagggcca ctttgtgaag 4260
ccggaggcct tcctgccttt ctcagcaggt gcctgtgggg agcccggctc cctgtcccct 4320
tccgtggagt cttgcagggg tatcacccag gagccaggct cactgacgcc cctcccctcc 4380
ccacaggccg ccgtgcatgc ctcggggagc ccctggcccg catggagctc ttcctcttct 4440
tcacctccct gctgcagcac ttcagcttct cggtgcccac tggacagccc cggcccagcc 4500
accatggtgt ctttgctttc ctggtgagcc catcccccta tgagctttgt gctgtgcccc 4560
gctagaatgg ggtacctagt ccccagcctg ctccctagcc agaggctcta atgtacaata 4620
aagcaatgtg gtagttccaa ctcgggtccc ctgctcacgc cctcgttggg atcatcctcc 4680
tcagggcaac cccacccctg cctcattcct gcttacccca ccgcctggcc gcatttgaga 4740
caggggtacg ttgaggctga gcagatgtca gttacccttg cccataatcc catgtccccc 4800
actgacccaa ctctgactgc ccagattggt gacaaggact acattgtcct ggcatgtggg 4860
gaaggggcca gaatgggctg actagaggtg tcagtcagcc ctggatgtgg tggagagggc 4920
aggactcagc ctggaggccc atatttcagg cctaactcag cccaccccac atcagggaca 4980
gcagtcctgc cagcaccatc acaacagtca cctcccttca tatatgacac cccaaaacgg 5040
aagacaaatc atggcgtcag ggagctatat gccagggcta cctacctccc agggctcagt 5100
cggc 5104
<210> 9
<211> 3507
<212> DNA
<213> Human Gene (Human Gene Sequence)
<400> 9
cacaccgggc acctgtactc ctcagccctt gggcagtgga cgggaccagg tgccgtggag 60
cagtgggagg cacccatccg ggaggctcgg gcctcgcagg gagcccaccg tagggaggct 120
tgggcatggc aggctgcaag tcctgagccc tgccccgcgg ggaggtgact gaggcctggc 180
gacaattcaa gtgtggtgag cgccggcagg ccagcagtac tgggggaccc ggtgccccct 240
ctgcagctgc tggcccaggt gctaagcccc tcactgcctg gggccagagg caccagccgg 300
ccgctccgag tgcagggccc gctgagcccc tgcccaccca gaactggtgc tggcccgcga 360
gcaacccagg ttcccgcaca cgcctctccc tccatacctc cccgcaagca gacggagccg 420
gctccagcct ccaccagtcc agagaggggc tcccacagtg cagcgctggg ctgaagggct 480
cctcaagtgt ggtcagagca gaagctgagg ccgaggaggc gctgagagcg agcgaggacc 540
accagcacgt tgacacctct caacctcacc acaggactgg ccacctctct gggccctcag 600
ggatgctgct gtctggaccc ctgaccagtg acgagttcgc actcagggcc aggctggcgc 660
tggaggagga cacttgtttg gctccaaccc taggtaccat cctcccagta gggatcaggc 720
agggcccaca ggcctgccct agggacagga gtcaaccttg gacccataag gcactggggc 780
gggcagagaa ggaggaggtg gcatgggcag ctgagagcca gagaccctga ccctagtcct 840
tgctctgcca ttaccccgtg tgaccccggg cccacccttc cccacccttc cccacccttc 900
cccaccccgg gcttctgttt cccttctgcc aacgagaagg ctgcttcacc tgccccgagt 960
cctgtcttcc tgctctgcct tctggggctg tggcccttgc tggcctggag ccccaaccaa 1020
gggcagggac tgctgtcctc cacgtctgtc ctcaccgaca taatgggctg ggctgggcac 1080
acaggcagtg cccaagagtt tctaatgagc atatgattac ctgagtcctg ggcagacctt 1140
cttagggaac agcctgggac agagaaccac agacactctg aggagccacc tgaggcctct 1200
tttgccagag gaccctacag cctccctggc agcagttccg ccagcatttc tgtaaatgcc 1260
ctcatgccag ggtgcggccc ggctgtcagc acgagaggga cgttggtctg tcccctggca 1320
ccgagtcagt cagaagggtg gccagggccc ccttgggccc ctccagagac aatccactgt 1380
ggtcacacgg ctcggtggca ggaagtgctg ttcctgcagc tgtggggaca gggagtgtgg 1440
atgaagccag gctgggtttg tctgaagacg gaggccccga aaggtggcag cctggcctat 1500
agcagcagca actcttggat ttattggaaa gattttcttc acggttctga gtcttggggg 1560
tgttagaggc tcagaaccag tccagccaga gctctgtcat gggcacgtag acccggtccc 1620
agggcctttg ctctttgctg tcctcagagg cctctgcaaa gtagaaacag gcagccttgt 1680
gagtcccctc ctgggagcaa ccaaccctcc ctctgagatg ccccggggcc aggtcagctg 1740
tggtgaaagg tagggatgca gccagctcag gggagtggcc cagagttcct gcccacccaa 1800
ggaggctccc aggaaggtca aggcacctga ctcctgggct gcttccctcc cctcccctcc 1860
ccaggtcagg aaggtgggaa agggctgggg tgtctgtgac cctggcagtc actgagaagc 1920
agggtggaag cagccccctg cagcacgctg ggtcagtggt cttaccagat ggatacgcag 1980
caacttcctt ttgaaccttt ttattttcct ggcaggaaga agagggatcc agcagtgaga 2040
tcaggcaggt tctgtgttgc acagacaggg aaacaggctc tgtccacaca aagtcggtgg 2100
ggccaggatg aggcccagtc tgttcacaca tggctgctgc ctctcagctc tgcacagacg 2160
tcctcgctcc cctgggatgg cagcttggcc tgctggtctt ggggttgagc cagcctccag 2220
cactgcctcc ctgccctgct gcctcccact ctgcagtgct ccatggctgc tcagttggac 2280
ccacgctgga gacgttcagt cgaagccccg ggctgtcctt acctcccagt ctggggtacc 2340
tgccacctcc tgctcagcag gaatggggct aggtgcttcc tcccctgggg acttcacctg 2400
ctctccctcc tgggataaga cggcagcctc ctccttgggg gcagcagcat tcagtcctcc 2460
aggtctcctg ggggtcgtga cctgcaggag gaataagagg gcagactggg cagaaaggcc 2520
ttcagagcac ctcatcctcc tgttctcaca ctggggtgtc acagtcctgg gaagttcttc 2580
cttttcagtt gagctgtggt aaccttgtga gtttcctgga gggggcctgc cactaccctt 2640
gggactccct gccgtgtgtc tgggtctaac tgagctctga aaggagagag ccccagccct 2700
gggccttcca ggggaagcct tacctcagag gttggcttct tcctactctt gactttgcgt 2760
ctctgcagag ggaggtggga ggggtgacac aaccctgaca cccacactat gagtgatgag 2820
tagtcctgcc ccgactggcc catcctttcc aggtgcagtc ccccttactg tgtctgccaa 2880
gggtgccagc acagccgccc cactccaggg gaagaggagt gccagccctt acccacctga 2940
gtgggcacag tgtagcattt attcattagc ccccacactg gcctgaccat ctcccctgtg 3000
ggctgcatga caaggagaga gaacaggctg aggtgagagc tactgtcaac acctaaacct 3060
aaaaaatcta taattgggct gggcagggtg gctcacgcct gtaatcccag cactttggga 3120
ggccgagatg ggtggatcac ctgaggtcag atgttcgaga ccagcctggc caacatggtg 3180
aaaccccgtc tctactaaaa atacaaaaaa ttagctgggc gtggtggtgg gtgcctgtaa 3240
tcccagctac tcaggaggct gaggcaggag aattgcttga acctgggagg cagaggctgc 3300
agtgagccga gatcgcatca ttgcactcca gcctggtcaa caagagtgaa actgtcttaa 3360
aaaaaaaatc tataattgat atctttagaa agataaaact ttgcattcat gaaataagaa 3420
taggagggtc taaaataaaa atgttcaaac acccaccacc actaattctt gacaaaaata 3480
tagtctgggt gccttagctc atgcctg 3507

Claims (10)

1. A CYP2D6 genotyping detection kit comprises a primer and a probe for detecting CYP2D6 x 10.
2. The test kit according to claim 1, wherein the sequences of the CYP2D6 x 10 primer and the probe are:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3'
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3'
CYP2D6 × 10 wild-type probe: 5'-CACGCTACCCACCAGG-3'
CYP2D6 × 10 mutant probe: 5'-ACGCTACTCACCAGG-3' are provided.
3. The detection kit according to one of claims 1 to 2, further comprising primers and probe sequences for detecting the internal reference gene ALB, wherein the primers and probe sequences are respectively:
ALB upstream primer: 5'-TTGTGGGCTGTAATCATCGTCTA-3'
ALB downstream primer: 5'-GTTCTCTTTCACTGACATCTGCAAA-3'
ALB probe: 5'-CCCACACAAATCTCTCCCTGGCATTG-3' are provided.
4. The test kit according to any one of claims 1 to 3, wherein the CYP2D6 x 10 wild type probe, CYP2D6 x 10 mutant probe, ALB probe are labeled with different fluorescent signaling groups, respectively.
5. The detection kit according to claim 4,
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNFQ.
ALB probe: CY5-CCCACACAAATCTCTCCCTGGCATTG-BHQ 3.
6. A method for detecting CYP2D6 gene polymorphism. The method comprises the following steps:
(1) extracting genomic DNA in a sample;
(2) performing fluorescent quantitative PCR on the DNA obtained in the step 1, wherein PCR reaction reagents comprise a primer and a probe for detecting CYP2D6 x 10 and a primer and a probe for detecting an internal reference gene ALB;
(3) and (4) interpretation of results: if CY5 and FAM have signals, the signal is CYP2D6 x 1 wild type; if CY5 and VIC have signals, the mutant is CYP2D6 x 10 homozygous mutant; if CY5, FAM and VIC have signals, the mutant is CYP2D6 x 1/x 10 hybrid mutant; if only CY5 has a signal, it is CYP2D6 × 5 type.
7. The method according to claim 6, wherein the sequences of the primer and probe for detecting CYP2D6 x 10 are:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3'
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3'
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNBNFQ
The sequences of primers and probes for detecting the internal reference gene ALB are respectively as follows:
ALB upstream primer: 5'-TTGTGGGCTGTAATCATCGTCTA-3'
ALB downstream primer: 5'-GTTCTCTTTCACTGACATCTGCAAA-3'
ALB probe: CY5-CCCACACAAATCTCTCCCTGGCATTG-BHQ 3.
8. A reagent composition capable of judging mutant types and deletion types of CYP2D6 genes comprises a fluorescent quantitative PCR amplification reagent, and is characterized in that the fluorescent quantitative PCR amplification reagent comprises a primer and a probe for detecting CYP2D6 x 10 and a primer and a probe for detecting internal reference genes ALB, wherein,
sequences of the primer and the probe for detecting CYP2D6 × 10 are respectively as follows:
CYP2D6 × 10 upstream primer: 5'-CCATTTGGTAGTGAGGCAGGT-3'
CYP2D6 × 10 downstream primer: 5'-ATGCAGCAGGTTGCCCA-3'
CYP2D6 × 10 wild-type probe: FAM-CACGCTACCCACCAGG-MGBNFQ
CYP2D6 × 10 mutant probe: VIC-ACGCTACTCACCAGG-MGBNBNFQ
The sequences of primers and probes for detecting the internal reference gene ALB are respectively as follows:
ALB upstream primer: 5'-TTGTGGGCTGTAATCATCGTCTA-3'
ALB downstream primer: 5'-GTTCTCTTTCACTGACATCTGCAAA-3'
ALB probe: CY5-CCCACACAAATCTCTCCCTGGCATTG-BHQ 3.
9. The reagent composition of claim 8, wherein the fluorescent quantitative PCR amplification reagent further comprises PCR Buffer, MgCl2, dNTP, and ROX fluorescent calibration solution.
10. The reagent composition of claim 8, further comprising a blood pretreatment reagent.
CN202011020314.XA 2020-09-24 2020-09-24 Reagent, detection method and kit for detecting CYP2D6 gene Pending CN112501265A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011020314.XA CN112501265A (en) 2020-09-24 2020-09-24 Reagent, detection method and kit for detecting CYP2D6 gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011020314.XA CN112501265A (en) 2020-09-24 2020-09-24 Reagent, detection method and kit for detecting CYP2D6 gene

Publications (1)

Publication Number Publication Date
CN112501265A true CN112501265A (en) 2021-03-16

Family

ID=74953712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011020314.XA Pending CN112501265A (en) 2020-09-24 2020-09-24 Reagent, detection method and kit for detecting CYP2D6 gene

Country Status (1)

Country Link
CN (1) CN112501265A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113755578A (en) * 2021-09-09 2021-12-07 上海普然生物科技有限公司 Detection kit for ondansetron and tropisetron metabolic markers and detection method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102549A1 (en) * 1999-12-30 2002-08-01 Katz David Aaron Amplification based polymorphism detection
CN101760528A (en) * 2008-12-26 2010-06-30 上海基康生物技术有限公司 Medicine metabolic relevant loci detection method
CN104263820A (en) * 2014-09-11 2015-01-07 广州基迪奥生物科技有限公司 Multi-site mutation detection method of CYP2D6 gene
CN105861703A (en) * 2016-05-16 2016-08-17 钟诗龙 Kit for simultaneously detecting multisite mutation of genes CYP2C19 and CYP2D6
CN109321651A (en) * 2018-10-29 2019-02-12 湖南健基生物技术有限公司 A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102549A1 (en) * 1999-12-30 2002-08-01 Katz David Aaron Amplification based polymorphism detection
CN101760528A (en) * 2008-12-26 2010-06-30 上海基康生物技术有限公司 Medicine metabolic relevant loci detection method
CN104263820A (en) * 2014-09-11 2015-01-07 广州基迪奥生物科技有限公司 Multi-site mutation detection method of CYP2D6 gene
CN105861703A (en) * 2016-05-16 2016-08-17 钟诗龙 Kit for simultaneously detecting multisite mutation of genes CYP2C19 and CYP2D6
CN109321651A (en) * 2018-10-29 2019-02-12 湖南健基生物技术有限公司 A kind of composition, kit, sample treatment and application detecting people CYP2D6 gene pleiomorphism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张志军等: "《体外诊断试剂检验技术》", 31 August 2019 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113755578A (en) * 2021-09-09 2021-12-07 上海普然生物科技有限公司 Detection kit for ondansetron and tropisetron metabolic markers and detection method and application thereof

Similar Documents

Publication Publication Date Title
Hosono et al. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection
US6528260B1 (en) Biallelic markers related to genes involved in drug metabolism
Haberstick et al. Genotyping of three single nucleotide polymorphisms following whole genome preamplification of DNA collected from buccal cells
CN106319040A (en) Kit for detecting human CYP2C19 genetic typing and detection method
Liang et al. The mutation spectrum of the phenylalanine hydroxylase (PAH) gene and associated haplotypes reveal ethnic heterogeneity in the Taiwanese population
CN112501265A (en) Reagent, detection method and kit for detecting CYP2D6 gene
JP5078358B2 (en) Interferon therapy responsiveness identification marker for renal cell carcinoma
CN110863040A (en) Method for detecting CYP3A5 gene polymorphism by fluorescent quantitative PCR
CN110423807B (en) Primer combination and kit for detecting deletion type alpha-thalassemia
CN106566880A (en) Hereditary hearing loss gene mutation detection kit
CN114085926A (en) Primer, probe, kit and detection method for SNP site polymorphism of ABCB1 gene C3435T
KR102511162B1 (en) HLA-DRB1 genotype analysis method using Korean-specific SNPs and optimized pipeline
EP1672069B1 (en) Canine cyp1a2 gene polymorphism
CN114457151B (en) Detection kit for detecting phenylalanine hydroxylase gene mutation and detection method thereof
CN117265138B (en) Primer and probe composition for cat blood group detection, detection method and application
KR102543976B1 (en) HLA-B genotype analysis method using Korean-specific SNPs and optimized pipeline
CN113416779B (en) Kit for detecting polymorphism of C667T locus of human MTHFR gene
CN116656804B (en) Genotyping kit for hereditary hearing loss
CN115725745B (en) SNP molecular marker related to sheep multi-thoracic vertebrae and amplification primer set and application
French et al. Detection of the factor V Leiden mutation by a modified photo-cross-linking oligonucleotide hybridization assay
CN113981058A (en) Primer group, probe, kit and method for detecting human HLA-B8 gene
US20120237932A1 (en) Methods and materials for assessing the cis/trans nature of humans having cyp2c19*2 and cyp2c19*17 alleles
CN117887836A (en) SNP marker for detecting weak expression RhD variant
CN110819722A (en) SYBR Green I detection primer, kit and detection method of CYP2D6 x 10 gene
US20090053716A1 (en) Method of detecting human cytochrome p450 (cyp) 2d6 gene mutation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination